Héctor García-Calderó
Publicacions destacades
-
Human amniotic stem cells improve hepatic microvascular dysfunction and portal hypertension in cirrhotic rats
Autors:Referència: Liver International 2020. -
Simvastatin Prevents Progression of Acute on Chronic Liver Failure in Rats With Cirrhosis and Portal Hypertension.
Autors:Referència: Gastroenterology 2018. -
Mitochondria-targeted antioxidant mitoquinone deactivates human and rat HSC and reduces portal hypertension in cirrhotic rats.
Autors:Referència: Liver International 2017. -
Simvastatin Attenuates Liver Injury in Rodents with Biliary Cirrhosis Submitted to Hemorrhage/Resuscitation
Autors:Referència: Shock 2017. -
Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats
Autors:Referència: Journal Of Hepatology 2016. -
Simvastatin prevents the aggravation of hepatic microvascular dysfunction caused by endotoxemia in cirrhotic rats
Autors:Referència: Hepatology 2015. -
Metformin reduces hepatic resistance and portal pressure in cirrhotic rats
Autors:Referència: American Journal Of Physiology-Gastrointestinal And Liver Physiology 2015. -
Simvastatin maintains function and viability of steatotic rat livers procured for transplantation
Autors:Referència: Journal Of Hepatology 2013. -
Simvastatin maintains function and viability of steatotic livers procured for transplantation
Autors:Referència: Hepatology 2012. -
Tempol administration, a superoxide dismutase mimetic, reduces hepatic vascular resistance and portal pressure in cirrhotic rats
Autors:Referència: Journal Of Hepatology 2011.